{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.923","value":"10.404"}]}],"title":"Day 1"},{"categories":[{"measurements":[{"groupId":"OG000","spread":"5.109","value":"11.949"}]}],"title":"Day 22"}],"denoms":[{"counts":[{"groupId":"OG000","value":"45"}],"units":"Participants"}],"description":"Whole blood samples were collected for pharmacokinetics analysis during the first (Day 1) and fourth (Day 22) treatments during cycle 1. Samples were collected on both occasions prior to dosing and at 0.5, 1, 3, 4.5, 6, 8 and 24 hour after the start of the bolus infusion.","dispersionType":"Standard Deviation","groups":[{"description":"PHASE I: Patients receive flavopiridol IV over 4½ hours on days 1, 8, 15, and 22. Treatment repeats every 6 weeks for up to 6 courses in the absence of disease progression or unacceptable toxicity.\n\nPHASE II: Patients receive flavopiridol\\* as in phase I at the MTD determined in phase I.\n\nalvocidib: Given IV","id":"OG000","title":"All Dose Levels of Alvocidib"}],"paramType":"MEAN","populationDescription":"total of 71 PK (Pharmacokinetic) profiles comprising 484 plasma concentration were determined for 45 of 46 patients following treatment","reportingStatus":"POSTED","timeFrame":"0, 1, 2, 3, 4, 6, 8, 12, 24, 48, 72, 96 hours post-dose on Days 1 and 22 of Cycle 1","title":"Pharmacokinetics (Area Under the Curve; AUC) of Flavopiridol","type":"SECONDARY","unitOfMeasure":"hr×μM"}